The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
(Approval lapsed) PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe (Ireland)
Section 19A approved medicine
(Approval lapsed) PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe (Ireland)
Section 19A approval holder
Echo Therapeutics Pty Ltd ABN 92 628 298 699
Phone
1300 848 328
Approved until
Status
Expired
Medicines in short supply/unavailable
PEGASYS peginterferon alfa-2a 135 micrograms/0.5mL injection pre-filled syringe - ARTG 91836
Indication(s)
Chronic Hepatitis C (CHC)
The combination of Pegasys and ribavirin is indicated for the treatment of chronic hepatitis C in patients who have received no prior interferon therapy (treatment-naïve patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin.
The combination of Pegasys and ribavirin is also indicated for the treatment of chronic hepatitis C patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy.
Pegasys monotherapy is indicated for the treatment of chronic hepatitis C in treatment-naïve patients.
Patients must be 18 years of age or older and have compensated liver disease.
Chronic Hepatitis B (CHB)
PEGASYS is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.
Images
